Eli Lilly’s Antibody Trial Is Paused Over Potential Safety Concern

Automatic TRANSCRIPT

Pharmaceutical giant Eli Lilly has suspended clinical trials of its monoclonal antibody drug over an unspecified potential safety concern president trump touted a similar drug produced by regeneration as a cure for covid nineteen. After he received a dose Soi hospitalized at Walter Reed Medical Center earlier this month both Eli Lilly and regeneration. For emergency use authorizations of their antibody

Coming up next